NBIX Quote, Financials, Valuation and Earnings

bluebird bio has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of -573.01%. Neurocrine Biosciences's return on equity of 13.72% beat bluebird bio's return on equity of -245.94%.

Neurocrine Biosciences has a consensus price target of $158.26, signalling upside risk potential of 56.1%. On the other hand bluebird bio has an analysts' consensus of $6.50 which suggests that it could grow by 57.01%. Given that bluebird bio has higher upside potential than Neurocrine Biosciences, analysts believe bluebird bio is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison bluebird bio has a beta of 0.431, suggesting its less volatile than the S&P 500 by 56.869%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than bluebird bio quarterly revenues of $10.6M. Neurocrine Biosciences's net income of $103.1M is higher than bluebird bio's net income of -$60.8M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 30.81x while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.46x versus 0.48x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of --. Neurocrine Biosciences's return on equity of 13.72% beat Perspective Therapeutics's return on equity of --.

Neurocrine Biosciences has a consensus price target of $158.26, signalling upside risk potential of 56.1%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 641.9%. Given that Perspective Therapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Perspective Therapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Perspective Therapeutics quarterly revenues of --. Neurocrine Biosciences's net income of $103.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 30.81x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.46x versus 12.56x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of 12.11%. Neurocrine Biosciences's return on equity of 13.72% beat Electromed's return on equity of 15.91%.

Neurocrine Biosciences has a consensus price target of $158.26, signalling upside risk potential of 56.1%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 62.35%. Given that Electromed has higher upside potential than Neurocrine Biosciences, analysts believe Electromed is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Electromed quarterly revenues of $16.3M. Neurocrine Biosciences's net income of $103.1M is higher than Electromed's net income of $2M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 30.81x while Electromed's PE ratio is 30.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.46x versus 3.42x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of 16.43% compared to Neurocrine Biosciences's net margin of 35.65%. Neurocrine Biosciences's return on equity of 13.72% beat Protalix BioTherapeutics's return on equity of 8.75%.

Neurocrine Biosciences has a consensus price target of $158.26, signalling upside risk potential of 56.1%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 455.56%. Given that Protalix BioTherapeutics has higher upside potential than Neurocrine Biosciences, analysts believe Protalix BioTherapeutics is more attractive than Neurocrine Biosciences.

Neurocrine Biosciences has a beta of 0.334, which suggesting that the stock is 66.575% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Neurocrine Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neurocrine Biosciences pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Neurocrine Biosciences quarterly revenues are $627.7M, which are larger than Protalix BioTherapeutics quarterly revenues of $18.2M. Neurocrine Biosciences's net income of $103.1M is higher than Protalix BioTherapeutics's net income of $6.5M. Notably, Neurocrine Biosciences's price-to-earnings ratio is 30.81x while Protalix BioTherapeutics's PE ratio is 87.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neurocrine Biosciences is 4.46x versus 4.06x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.